AbbVie (ABBV) Short term Debt (2012 - 2026)

AbbVie (ABBV) has reported Short term Debt for 15 consecutive years, with $8.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Short term Debt rose 50.13% year-over-year to $8.3 billion in Q2 2026; TTM through Jun 2026 was $8.3 billion, a 50.13% increase from a year earlier, with the FY2025 full-year figure at $6.1 billion, down 10.99% from the prior year.
• Short term Debt was $8.3 billion for Q2 2026 at AbbVie, roughly flat from $8.3 billion in the prior quarter.
• Over five years, Short term Debt peaked at $12.6 billion in Q2 2024 and troughed at $2.8 billion in Q1 2023.
• A 5-year average of $7.4 billion and a median of $7.0 billion in 2023 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt plunged 71.83% in 2023 and jumped 264.04% in 2024, its largest moves.
• Over 5 years, Short term Debt stood at $4.1 billion in 2022, then soared by 73.91% to $7.2 billion in 2023, then retreated by 5.38% to $6.8 billion in 2024, then slipped by 10.99% to $6.1 billion in 2025, then jumped by 37.73% to $8.3 billion in 2026.
• The last three Short term Debt figures came in at $8.3 billion (Q2 2026), $8.3 billion (Q1 2026), and $6.1 billion (Q4 2025), per Business Quant data.